| Quantity | 1 mg, 5 mg, 10 mg, 25 mg | 10 mM * 1 mL, 5 mg, 10 mg, 25 mg | 10 mM * 1 mL, 1 g, 5 g, 25 g | 5 mg, 10 mg, 25 mg, 50 mg | 1 mg, 5 mg, 10 mg, 25 mg |
| Description | CPP9 TFA is a small, amphipathic, cyclic cell penetrating peptide (CPP). CPPs bind directly to the plasma membrane phospholipids and enter mammalian cells via endocytosis, followed by efficient release from the endosome. CPP9 TFA can be used for intracellular delivery of therapeutic agents and CPP9 TFA is a small, amphipathic, cyclic cell penetrating peptide (CPP). CPPs bind directly to the plasma membrane phospholipids and enter mammalian cells via endocytosis, followed by efficient release from the endosome. CPP9 TFA can be used for intracellular delivery of therapeutic agents and chemical probes[1]... Read More | DAMGO TFA is a µ-opioid receptor (µ-OPR ) selective agonist with a Kd of 3.46 nM for native µ-OPR[1] | Dipeptide 2 (N-Valyltryptophan; Val-Trp) is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient[1]. Dipeptide 2 is an angiotensin-converting Enzyme (ACE)[2] | HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases[1][2]... Read More | Neurotensin, a gut tridecapeptide, acts as a potent cellular mitogen for various colorectal and pancreatic cancers which possess high-affinity neurotensin receptors (NTR) |